Clinical Trial + Cellcept - Could this be a good fit for you?

Check out this Lupus clincial trial, sponsored by Hoffmann-Roche, the folks who bring us Cellcept - my favorite!  They are currently accepting participants for NOBILITY, a Phase II research trial.  I like this one in particular because patients remain on Cellcept as part of the study.

Here are details, and a few of the criteria for participation. Click here to go straight to the clinical trial website. As always, discuss the study thoroughly with your doctor to determine if this trial might be for you!

Details: 

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Hoffmann-Roche and Genentech are currently enrolling both sites and patients in a global, Phase II clinical research study called NOBILITY (NCT02550652). The goal of the study is to evaluate the safety and effectiveness of an investigational medicine, obinutuzumab, for adults with lupus nephiritis.

Estimated Enrollment:	120
Actual Study Start Date:	November 13, 2015
Estimated Study Completion Date:	August 29, 2020
Estimated Primary Completion Date:	August 29, 2019 (Final data collection date for primary outcome measure)

Eligibility:  

Ages Eligible for Study:	18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Inclusion Criteria:

• Diagnosis of Systemic Lupus Erythematosus (SLE), according to current American College of Rheumatology (ACR) criteria
• Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN as evidenced by renal biopsy performed within 6 months prior to or during screening. Participants may co-exhibit Class V disease in addition to either Class III or Class IV disease